SG10201400388QA - IgE CH3 peptide vaccine - Google Patents

IgE CH3 peptide vaccine

Info

Publication number
SG10201400388QA
SG10201400388QA SG10201400388QA SG10201400388QA SG10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA SG 10201400388Q A SG10201400388Q A SG 10201400388QA
Authority
SG
Singapore
Prior art keywords
ige
peptide vaccine
vaccine
peptide
Prior art date
Application number
SG10201400388QA
Inventor
Alan Daniel Brown
Brian Robert Champion
Clare Christy
David Paul Gervais
Lyn Howard Jones
Anne Maria Kristina Kjerrstrom
David Cameron Pryde
Lee Richard Roberts
David Michael Wyatt
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42035836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201400388Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of SG10201400388QA publication Critical patent/SG10201400388QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
SG10201400388QA 2008-12-09 2009-12-04 IgE CH3 peptide vaccine SG10201400388QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12098908P 2008-12-09 2008-12-09

Publications (1)

Publication Number Publication Date
SG10201400388QA true SG10201400388QA (en) 2014-05-29

Family

ID=42035836

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012088373A SG186611A1 (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine
SG10201400388QA SG10201400388QA (en) 2008-12-09 2009-12-04 IgE CH3 peptide vaccine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012088373A SG186611A1 (en) 2008-12-09 2009-12-04 Ige ch3 peptide vaccine

Country Status (22)

Country Link
US (3) US8298547B2 (en)
EP (2) EP2376108B1 (en)
JP (4) JP5209800B2 (en)
KR (3) KR101644221B1 (en)
CN (1) CN102245198B (en)
AR (1) AR074505A1 (en)
AU (1) AU2009325950B2 (en)
BR (1) BRPI0922561A2 (en)
CA (1) CA2744754A1 (en)
CO (1) CO6561830A2 (en)
DK (1) DK2376108T3 (en)
ES (1) ES2622562T3 (en)
HK (1) HK1163511A1 (en)
IL (1) IL213029A0 (en)
MX (2) MX2011006077A (en)
NZ (2) NZ592977A (en)
PE (2) PE20110891A1 (en)
RU (1) RU2495049C2 (en)
SG (2) SG186611A1 (en)
TW (1) TWI387463B (en)
WO (1) WO2010067286A2 (en)
ZA (1) ZA201104072B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566245A (en) * 2005-08-11 2012-04-27 Matossian Rogers Arpi Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
PL2376107T3 (en) 2008-12-09 2014-09-30 Coley Pharm Group Inc Immunostimulatory oligonucleotides
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
PL2714908T3 (en) 2011-05-26 2018-07-31 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
US9359602B2 (en) * 2011-05-26 2016-06-07 Intervet Inc. Immunostimulatory oligodeoxynucleotides
EP2804624B1 (en) 2012-01-19 2018-12-26 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
CN104395337A (en) * 2012-06-18 2015-03-04 日本全药工业株式会社 Ige peptide vaccine
EP3166630A4 (en) 2014-07-07 2018-03-28 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
CA2954278A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
JP6876601B2 (en) 2014-07-10 2021-05-26 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ Substances and methods for use in the prevention and / or treatment of Huntington's disease
WO2017057540A1 (en) * 2015-09-30 2017-04-06 塩野義製薬株式会社 Nucleic acid derivative having immunostimulatory activity
KR101876620B1 (en) * 2015-10-27 2018-07-09 대구한의대학교산학협력단 The norovirus detection chip using peptide binders via peptidomimetics for human and the manufacturing method
WO2017120576A1 (en) 2016-01-07 2017-07-13 Duke University Cancer vaccines and methods of delivery
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
BR112019019177B8 (en) * 2017-03-29 2022-09-13 Shionogi & Co PHARMACEUTICAL COMPOSITION COMPRISING NUCLEIC ACID DERIVATIVES HAVING IMMUNOSTIMULATING ACTIVITY
CA3192500A1 (en) 2020-09-17 2022-03-24 Laurent REBER Immunogenic product comprising an ige fragment for treating ige-mediated inflammatory disorders
WO2023192203A2 (en) * 2022-03-28 2023-10-05 The Regents Of The University Of California Novel plant virus and bacteriophage vaccines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (en) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド Oligonucleotide therapeutic agent and method for producing the same
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
JPS63225397A (en) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd Novel peptide having antiallergic action
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
US5258289A (en) * 1990-09-05 1993-11-02 Davis Claude G Method for the selecting of genes encoding catalytic antibodies
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
SE9102808L (en) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo VACCIN, HOW TO USE HUMAN USE, WILL BE INTENDED TO EFFECT THE SYMPTOMS OR PREVENT THE RISE OF IGE-MEDIATED ALLERGIC REACTIONS
KR100278157B1 (en) 1992-06-25 2001-01-15 장 스테판느 Vaccine Compositions Containing Supplements
DK0812593T4 (en) 1993-03-23 2008-05-13 Smithkline Beecham Biolog Vaccine preparations containing 3-O-deacylated monophosphoryl lipid-A
DE4321946A1 (en) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonic acid esters, process for their preparation and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ES2190799T5 (en) 1996-03-01 2008-08-16 Novartis Ag PEPTIDIC IMMUNOGENS FOR VACCINATION AND TREATMENT AGAINST ALLERGY.
ID18046A (en) 1996-08-20 1998-02-19 Takeda Chemical Industries Ltd COMPOUND, MIXED CYCLE, MANUFACTURE AND USE OF IT.
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE292980T1 (en) 1996-10-11 2005-04-15 Univ California IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
JP2001513776A (en) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
DE69911175T2 (en) 1998-02-12 2004-07-29 Apovia, Inc., San Diego STRATEGICALLY MODIFIED HEPATITIS B CORE PROTEINS AND THEIR DERIVATIVES
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
JP2002510644A (en) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション Methods and products for immune system stimulation using immunotherapeutic oligonucleotides and cytokines
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
DE69922873T2 (en) * 1998-04-09 2005-12-29 Idexx Laboratories, Inc. Specific binding proteins for the treatment of allergies in dogs
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ATE434440T1 (en) 1998-09-03 2009-07-15 Novartis Vaccines & Diagnostic FGF-2 ANGIOGENIC EFFECTIVE UNIT DOSE AND METHOD OF USE THEREOF
ES2188003T3 (en) 1998-09-18 2003-06-16 Pentapharm Ag UROQUINASE INHIBITORS.
ATE357252T1 (en) 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa ADJUVANCE SYSTEMS AND VACCINES
AU770802B2 (en) 1998-10-21 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Virus-like particles for the induction of autoantibodies
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
DK1119630T3 (en) 1998-11-05 2006-05-15 Powderject Vaccines Inc Nucleic acid constructs for genetic immunization
RU2245163C2 (en) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Composition, method for producing artificial ordered and repetitions-containing antigen matrix, method for carrying out therapy and immunization
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (en) 1999-02-17 2016-06-02 Csl Limited Immunogenic complexes and related methods
US20030170229A1 (en) * 1999-02-25 2003-09-11 Smithkline Beecham Biologicals S.A. Vaccine
HUP0105490A3 (en) 1999-02-25 2002-05-28 Peptide Therapeutics Ltd Cambr Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
PL203917B1 (en) 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Vaccine
JP2002539818A (en) * 1999-03-30 2002-11-26 アイデックス ラボラトリーズ インコーポレイテッド Specific binding proteins for treating dog allergy
CZ303515B6 (en) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvant compositions
TR200200777T2 (en) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. At least one non-ionic surfactant adjuvant with polyoxyethylene alkyl ether or ester.
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
EP1220684B2 (en) 1999-09-27 2010-07-14 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EA200201077A1 (en) 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед COW ANTIGENIC CHEMICAL PROTEINS OF HEPATITIS B
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
DK1294893T3 (en) 2000-06-22 2006-07-03 Ucb Pharma Ltd Modification of hepatitis B core antigen
WO2002005690A1 (en) 2000-07-15 2002-01-24 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
EP2065052A3 (en) 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002339224B2 (en) * 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1517702A4 (en) 2002-02-21 2006-05-03 Apovia Inc IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CU22983A1 (en) * 2002-05-08 2004-09-09 Inst Finlay VACCINE COMPOSITION AGAINST ALLERGIES AND METHOD FOR OBTAINING AND EMPLOYMENT IN THE TREATMENT OF THE SAME
RU2324704C2 (en) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Antigen molecular massifs
ATE546156T1 (en) 2002-12-10 2012-03-15 Sanofi Pasteur Biologics Co STABILIZED IMMUNOGENIC CHIMERIC HBC PARTICLES
EP1605973B1 (en) * 2003-03-26 2012-09-26 Cytos Biotechnology AG Packaging of immunostimulatory oligonucleotides into virus-like particles: methods of preparation and uses
SG183683A1 (en) 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
KR100958505B1 (en) 2004-07-18 2010-05-17 씨에스엘 리미티드 Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
WO2006134423A2 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
DK2405002T3 (en) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Compositions and methods for oligonukleotidformuleringer
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
PE20081899A1 (en) 2007-04-02 2009-01-26 Pfizer ANTI-IGE ANTIBODIES
US20100203083A1 (en) * 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
US11780237B2 (en) 2015-06-23 2023-10-10 Ripples Ltd Method and apparatus for printing on a drink

Also Published As

Publication number Publication date
AU2009325950B2 (en) 2013-03-07
TW201036632A (en) 2010-10-16
US20120294848A1 (en) 2012-11-22
CN102245198A (en) 2011-11-16
MX2011006077A (en) 2011-09-01
ZA201104072B (en) 2012-02-29
MX337723B (en) 2016-03-15
JP2012511322A (en) 2012-05-24
IL213029A0 (en) 2011-07-31
JP2012255006A (en) 2012-12-27
JP5209800B2 (en) 2013-06-12
AR074505A1 (en) 2011-01-19
KR101413844B1 (en) 2014-06-30
PE20110891A1 (en) 2011-12-23
NZ604186A (en) 2014-07-25
JP2016164156A (en) 2016-09-08
PE20142330A1 (en) 2015-01-14
CA2744754A1 (en) 2010-06-17
US8475801B2 (en) 2013-07-02
BRPI0922561A2 (en) 2020-08-11
KR20110094134A (en) 2011-08-19
WO2010067286A2 (en) 2010-06-17
CO6561830A2 (en) 2012-11-15
KR20150056881A (en) 2015-05-27
KR20130032390A (en) 2013-04-01
JP5964280B2 (en) 2016-08-03
EP2376108B1 (en) 2017-02-22
US20140017239A1 (en) 2014-01-16
US20100158933A1 (en) 2010-06-24
NZ592977A (en) 2013-01-25
TWI387463B (en) 2013-03-01
JP2014012009A (en) 2014-01-23
SG186611A1 (en) 2013-01-30
US9216229B2 (en) 2015-12-22
KR101644221B1 (en) 2016-07-29
RU2011121043A (en) 2013-01-20
AU2009325950A1 (en) 2010-06-17
HK1163511A1 (en) 2012-09-14
RU2495049C2 (en) 2013-10-10
EP2865389A1 (en) 2015-04-29
WO2010067286A3 (en) 2010-08-05
JP5367137B2 (en) 2013-12-11
US8298547B2 (en) 2012-10-30
CN102245198B (en) 2016-08-17
KR101634058B1 (en) 2016-06-27
ES2622562T3 (en) 2017-07-06
EP2376108A2 (en) 2011-10-19
DK2376108T3 (en) 2017-04-24

Similar Documents

Publication Publication Date Title
HK1163511A1 (en) Ige ch3 peptide vaccine ige ch3
IL219048A (en) Urcl10 derived peptide vaccines
ZA201101481B (en) Vaccine
HRP20151124T1 (en) Vaccine
IL208660A0 (en) Coccididosis vaccines
GB0822001D0 (en) Vaccine
GB0810710D0 (en) Vaccine
ZA201007402B (en) Vaccine
GB0920981D0 (en) Peptides
IL199622A0 (en) Foxp3 peptide vaccine
GB0816284D0 (en) Vaccine
GB0816447D0 (en) Vaccine
HK1173358A1 (en) Fviii-derived peptides fviii
GB0801326D0 (en) Vaccines
EP2439209A4 (en) Endokinin c/d-origin peptides
GB0920987D0 (en) Peptides
GB0817978D0 (en) Peptides
GB0815673D0 (en) Peptides
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
AP2010005295A0 (en) Vaccine
GB0810914D0 (en) Vaccine
GB0820478D0 (en) Vaccine
AU2008267307A1 (en) Vaccine
GB0802108D0 (en) Vaccine